Reviewed by Michael Gill, B. Sc.
25 Bone Marrow Transplant Clinical Trials Near Me
Top Cities for Bone Marrow Transplant Clinical Trials
Image of Boston in Massachusetts.
Boston
44Active Trials
Massachusetts General HospitalTop Active Site
Image of New York in New York.
New York
43Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Bone Marrow Transplant Clinical Trials by Phase of Trial
Phase < 1 Bone Marrow Transplant Clinical Trials
5Active Bone Marrow Transplant Clinical Trials
5Number of Unique Treatments
3Number of Active Locations
Microbial Transplant Therapyabdominal wall transplantationGlecaprevir/pibrentasvirMRD-BMT with Fludarabine-based RIC for Acquired AAFluorothymidine F-18
Most Recent Bone Marrow Transplant Clinical Trials

What Are Bone Marrow Transplant Clinical Trials?

Bone marrow transplant clinical trials study the ways to improve outcomes for patients who receive bone marrow transplants.

Why Are Bone Marrow Transplants Being Studied in Clinical Trials?

Bone marrow transplants continue to be studied in clinical trials for various reasons. These include improving patient experience and healing, improving the success of bone marrow transplants, and reducing long-term health effects and conditions following transplants.

How Do Bone Marrow Transplants Work?

Bone marrow transplants are done when bone marrow is not functioning properly. This usually happens as a result of serious diseases, including cancer. When marrow function is impacted, the body cannot make red and white blood cells and platelets.

A bone marrow transplant involves taking healthy red blood cells from a donor match. The recipient undergoes a chemo regimen to prepare for the transplant, which is injected into the bloodstream through an IV.

Finding a bone marrow donor match can be difficult. Roughly 70 percent of patients do not have a match in their family, which necessitates searching through public databases such as Be The Match. In some cases, patients may receive an autologous bone marrow transplant, meaning that their own red blood cells are stored for later transplant.

What Are Some of The Breakthrough Clinical Trials Involving Bone Marrow Transplants?

Bone marrow transplants continue to be studied in clinical trials. Some of the most important recent findings include:

2019: A new drug may reduce side effects of host rejection - This study indicated successful treatment with ibrutinib. This drug fights graft versus host disease, or GVHD, a condition where a bone marrow recipient’s body rejects the donor cells, leading to many chronic health problems. Ibrutinib may have fewer side effects than traditional GVHD treatments such as steroids.

2022: Fetal liver cells may have potential for bone marrow recipients - This study examined the growth and self-replication capabilities of fetal liver cells. The findings have the potential to help scientists understand how to help healthy cells replicate, which could be promising for patients needing an autologous bone marrow transplant.

2016: Antibody treatments - This study found that treatments with antibodies may prepare donors for transplants more effectively than chemo and radiation. This method removes 98 percent of damaged red blood cells without the side effects of traditional treatments, indicating that it may be a healthier and equally effective treatment for transplant recipients.

Who Are The Key Opinion Leaders on Bone Marrow Transplant Clinical Trials?

Shakila P. Khan, M.D. is a pediatric oncology doctor specializing in bone marrow transplants. She has worked extensively with the Mayo Clinic Transplant Center and Comprehensive Cancer Center.

David Dingli, M.D., Ph.D. is an oncologist and researcher focusing on transplants and the immune system to improve surgery outcomes.

Esperanza B. Papadopoulos, M.D. is an oncologist and clinical director of the Adult Bone Marrow Transplantation Inpatient Department at Memorial Sloan Kettering Cancer Center. She has participated in extensive clinical research on post-transplant cell rejection and infection.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: November 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. Erratum in: Am J Respir Crit Care Med. 2016 May 15;193(10):1185. https://pubmed.ncbi.nlm.nih.gov/120911802 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/314019033 Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, Puhan MA, Hoogendoorn M, Garrod R, Schols AM, Carlin B, Benzo R, Meek P, Morgan M, Rutten-van Mölken MP, Ries AL, Make B, Goldstein RS, Dowson CA, Brozek JL, Donner CF, Wouters EF; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. doi: 10.1164/rccm.201309-1634ST. Erratum in: Am J Respir Crit Care Med. 2014 Jun 15;189(12):1570. https://pubmed.ncbi.nlm.nih.gov/241278114 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. https://pubmed.ncbi.nlm.nih.gov/294338505 Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980 Aug;66(8):271-3. https://pubmed.ncbi.nlm.nih.gov/64504266 Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999 Jul;54(7):581-6. https://pubmed.ncbi.nlm.nih.gov/103772017 Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Curr Opin Hematol. 2021 Mar 1;28(2):110-121. doi: 10.1097/MOH.0000000000000637. Review. https://pubmed.ncbi.nlm.nih.gov/333947228 Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005 Dec 3;366(9501):1925-34. https://pubmed.ncbi.nlm.nih.gov/163256949 Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994 Jun 9;330(23):1639-44. https://pubmed.ncbi.nlm.nih.gov/799340910 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Review. https://pubmed.ncbi.nlm.nih.gov/20175033